AAV Vectored Immunoprophylaxis for Prevention of Respiratory Infectious Diseases

This project aims to provide an alternative therapeutic for the prevention and treatment of the virus responsible for COVID-19, SARS-CoV-2, as well as respiratory syncytial virus and influenza. Using a single viral vector platform, we will deliver antibodies from human survivors of these diseases to provide sustained levels of protection against the virus for all patients, including the elderly and immunocompromised. This project will help Avamab Pharma Inc.

AAV Vectored Immunoprophylaxis for Prevention of SARS-CoV-2 in the Elderly and Immunocompromised

As of May 1st, 2020, over 3.2 million cases of COVID-19 have been confirmed, resulting in over 233,000 deaths globally. This project aims to provide an alternative vaccine for the prevention and treatment COVID-19 in high risk individuals, mainly the elderly and immunocompromised, who do not respond well to tranditional vaccination.